Drug Profile
Tirzepatide - Eli Lilly and Company
Alternative Names: GIP/GLP-1 RA; LY-3298176; Mounjaro; ZepboundLatest Information Update: 09 Feb 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Mitsubishi Tanabe Pharma Corporation
- Class Antihyperglycaemics; Glucagon-like peptides; Heart failure therapies; Hepatoprotectants; Obesity therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Obesity; Type 2 diabetes mellitus
- Phase III Cardiovascular disorders; Heart failure; Sleep apnoea syndrome
- Phase II Kidney disorders; Non-alcoholic steatohepatitis
Most Recent Events
- 06 Feb 2024 Efficacy data from the phase II SYNERGY-NASH trial in Non-alcoholic steatohepatitis released by Eli Lilly and Company
- 12 Dec 2023 Updated efficacy and adverse events data from a phase III SURMOUNT-4 trial in Obesity released by Eli Lilly and Company
- 05 Dec 2023 Launched for Obesity in USA (SC)